Close Menu

Now, Developer

23andMe has licensed an antibody it developed to treat inflammatory diseases to the Spanish drugmaker Almirall, according to Bloomberg

"This is a seminal moment for 23andMe," Emily Drabant Conley, the vice president of business development at 23andMe, tells Bloomberg. "We've now gone from database to discovery to developing a drug."

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

According to BBC News, the global vaccine-sharing initiative has sent its first shipment, which arrived in Ghana this week.

CNN reports that a US Food and Drug Administration document says Johnson & Johnson's SARS-CoV-2 vaccine meets the requirements to receive an Emergency Use Authorization.

Researchers in France are developing a new, fast test for SARS-CoV-2 that initial testing indicates may be highly accurate, the Guardian says.

In Cell this week: analysis of fitness patterns among SARS-CoV-2 isolates, single-cell transcriptome analysis of immune features in COVID-19, and more.